文献速递药物不良反应与药物警戒

药物开发中的药物警戒尽职调查:风险识别、合规评估与战略决策的实用手册

Pharmacovigilance Due Diligence in Drug Development: A Practical Playbook for Risk Identification, Compliance Assessment, and Strategic Decision Making.
PubMed 文献 · Drug Saf · 2025-12-16

本文聚焦药物警戒(PV)与安全专家在制药行业尽职调查(DD)中的独特作用,梳理必须回答的关键安全性问题,提示器官特异性毒性、标签责任或风险管理负担等潜在警示信号,并基于行业经验与监管先例提供结构化指导,提出系统性安全DD方法、操作手册及含颜色编码分类框架的检查清单,以支持更知情、主动且风险校准的决策。

要点

  • PV专家在DD中需评估安全性数据包的稳健性及获益-风险达成的可能性。
  • 需识别器官特异性毒性、标签责任、风险管理负担等安全性警示信号。
  • 提出含颜色编码分类框架的检查清单以系统化安全DD。

核心结论

  • 安全评估在DD中对产品能否获批、维持有利获益-风险比及市场准入起关键作用。
  • 提出系统性安全DD方法(含操作手册与颜色编码检查清单)以支持风险校准决策。

研究设计与样本

  • 本文为基于行业经验与监管先例的实践指导文章,非原始研究。

主要发现

  • 需回答关键安全性问题并识别器官特异性毒性、标签责任或风险管理负担等警示信号。
  • 需预测实现积极获益-风险特征的可能性,并识别从黑框警告到撤市风险的可预见安全性障碍。

关键数值与推荐

  • 提出含颜色编码分类框架的检查清单作为安全DD的结构化工具。

临床怎么用

  • 在许可引进或收购等交易中,由PV与安全专家系统评估安全性数据包稳健性。
  • 利用操作手册与检查清单前瞻性识别可能延迟批准或降低产品价值的安全性障碍。

局限性

  • 该领域此前无正式框架,本文基于行业经验与监管先例提供结构化指导。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the pharmaceutical industry, due diligence (DD) is a critical, cross-functional process used to evaluate the scientific and regulatory viability of products, particularly during in-licensing or acquisition. Among the various dimensions assessed, safety evaluation plays a pivotal role in determining whether a product is likely to achieve regulatory approval, maintain a favourable benefit-risk balance, and support sustainable market access. This article focuses on the unique role of pharmacovigilance (PV) and safety experts in the DD process. It outlines the key safety-related questions that must be addressed, highlights potential red flags-such as organ-specific toxicities, labelling liabilities, or risk management burdens-and provides practical considerations for evaluating the robustness of the safety data package. Drawing on extensive industry experience and regulatory precedents, this manuscript offers structured guidance for an area where no formal framework exists. It emphasizes the importance of forecasting the likelihood of achieving a positive benefit-risk profile and identifying foreseeable safety-related barriers-ranging from boxed warnings to withdrawal risk-that could delay approval or diminish product value. By proposing a systematic approach to safety DD, including a playbook and an inclusive checklist with colour-coded categorization framework, this paper aims to support more informed, proactive, and risk-calibrated decision making in pharmaceutical transactions.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Youssef A, Hammad TA. Pharmacovigilance Due Diligence in Drug Development: A Practical Playbook for Risk Identification, Compliance Assessment, and Strategic Decision Making. Drug Saf. 2025. PMID: 41400880. doi:10.1007/s40264-025-01640-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。